WO2019004792A3 - 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도 - Google Patents

인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도 Download PDF

Info

Publication number
WO2019004792A3
WO2019004792A3 PCT/KR2018/007433 KR2018007433W WO2019004792A3 WO 2019004792 A3 WO2019004792 A3 WO 2019004792A3 KR 2018007433 W KR2018007433 W KR 2018007433W WO 2019004792 A3 WO2019004792 A3 WO 2019004792A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiac stem
human
preparation
microspheroid
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/007433
Other languages
English (en)
French (fr)
Other versions
WO2019004792A2 (ko
WO2019004792A9 (ko
Inventor
이승진
양영일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Industry Academic Cooperation Foundation of Inje University
Original Assignee
Ewha Womans University
Industry Academic Cooperation Foundation of Inje University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University, Industry Academic Cooperation Foundation of Inje University filed Critical Ewha Womans University
Priority to US16/627,258 priority Critical patent/US11692171B2/en
Publication of WO2019004792A2 publication Critical patent/WO2019004792A2/ko
Publication of WO2019004792A3 publication Critical patent/WO2019004792A3/ko
Publication of WO2019004792A9 publication Critical patent/WO2019004792A9/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 인간 유래 심장 줄기세포를 이용한 미세구의 제조 방법 및 이의 심근 재생 효과를 이용한 허혈성 심장질환 치료 용도에 관한 것이다. 본 발명에서 제공하는 심장 줄기세포를 이용한 미세구는 기존의 심장 줄기세포와 비교하여 우수한 심근분화능과 재생 치료능을 가져 심근경색과 같은 허혈성 심장질환의 치료 용도로 사용할 수 있을 것이다.
PCT/KR2018/007433 2017-06-30 2018-06-29 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도 Ceased WO2019004792A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/627,258 US11692171B2 (en) 2017-06-30 2018-06-29 Preparation method of human-derived cardiac stem cell spheroid and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170083057A KR102182513B1 (ko) 2017-06-30 2017-06-30 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도
KR10-2017-0083057 2017-06-30

Publications (3)

Publication Number Publication Date
WO2019004792A2 WO2019004792A2 (ko) 2019-01-03
WO2019004792A3 true WO2019004792A3 (ko) 2019-04-11
WO2019004792A9 WO2019004792A9 (ko) 2019-05-31

Family

ID=64742499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007433 Ceased WO2019004792A2 (ko) 2017-06-30 2018-06-29 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도

Country Status (3)

Country Link
US (1) US11692171B2 (ko)
KR (1) KR102182513B1 (ko)
WO (1) WO2019004792A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4101440A4 (en) * 2020-02-04 2024-02-21 Hierabio Inc. COMPOSITION FOR INTRAPERICARDIAL INJECTION WITH STEM CELLS AND USE THEREOF
KR102367101B1 (ko) 2020-03-09 2022-02-23 부산대학교 산학협력단 심장 보호 효과를 갖는 신규 화합물 및 이를 이용한 줄기세포 배양용 배지조성물
WO2022255728A1 (ko) * 2021-05-31 2022-12-08 서울대학교병원 조직 재생 촉진용 세포 스페로이드의 제조 및 표준화
KR102455288B1 (ko) 2021-12-03 2022-10-17 중앙대학교 산학협력단 신경구로부터의 생식선 줄기세포로의 전환방법 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267921A1 (en) * 2004-11-08 2008-10-30 Johns Hopkins University Cardiac Stem Cells
JP2012523238A (ja) * 2009-04-09 2012-10-04 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 三次元繊維芽細胞構築物の細胞播種および共培養
WO2014141220A1 (en) * 2013-03-15 2014-09-18 Coretherapix Slu Adult cardiac stem cell population
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
US20160244723A1 (en) * 2003-07-31 2016-08-25 Universita Degli Studi Di Roma "La Sapienza" Cardiac stem cells and uses of same in cardiac repair

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101389850B1 (ko) 2012-05-04 2014-04-29 이화여자대학교 산학협력단 심장전구세포의 배양방법 및 그 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160244723A1 (en) * 2003-07-31 2016-08-25 Universita Degli Studi Di Roma "La Sapienza" Cardiac stem cells and uses of same in cardiac repair
US20080267921A1 (en) * 2004-11-08 2008-10-30 Johns Hopkins University Cardiac Stem Cells
JP2012523238A (ja) * 2009-04-09 2012-10-04 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 三次元繊維芽細胞構築物の細胞播種および共培養
WO2014141220A1 (en) * 2013-03-15 2014-09-18 Coretherapix Slu Adult cardiac stem cell population
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法

Also Published As

Publication number Publication date
US11692171B2 (en) 2023-07-04
WO2019004792A2 (ko) 2019-01-03
KR102182513B1 (ko) 2020-11-25
US20200131479A1 (en) 2020-04-30
WO2019004792A9 (ko) 2019-05-31
KR20190003871A (ko) 2019-01-10

Similar Documents

Publication Publication Date Title
ZA202210065B (en) Interleukin-21 muteins and methods of treatment
WO2019004792A3 (ko) 인간 유래 심장 줄기세포 미세구의 제조 방법 및 용도
WO2016081748A3 (en) Antibodies against cd73 and uses thereof
MX2021005326A (es) Compuestos de pirimidinodiona contra estados cardiacos.
WO2011057249A3 (en) Treatment of heart disease
EP3593809A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING MMR1 POSITIVE MESENCHYMATIC STEM CELLS IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF A FIBROSIS-ASSOCIATED DISEASE, ITS PREPARATION PROCESS, AND PROCESS FOR THE PROPHYLACTIC TREATMENT OF FIBROSIS-ASSOCIATED DISEASE OR A FIBROSIS-ASSOCIATED THERAPEUTIC TREATMENT, AND PROCESS FOR THE PROPHYLACTIC TREATMENT OF FIBROSIS ASSOCIATED OR THERAPEUTIC TREATMENT MMR-POSITIVE MESENCHYMATIC STEM CELLS
WO2011057251A3 (en) Treatment of heart disease
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
SG10201902574RA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2012135868A3 (en) Compositions and methods for the treatment and prevention of cardiac ischemic injury
JP2015159895A5 (ko)
TW201613932A (en) Organic compounds
AU2016255474A8 (en) Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease
WO2010007031A3 (en) Methods for improving cardiac differentiation of human embryonic stem cells
WO2016022536A3 (en) Inhibitors of myh7b and uses thereof
MX2019004314A (es) Composición de apósito tópico para el tratamiento de tejido cutáneo dañado.
MX2021007885A (es) Metodos y composiciones para el tratamiento de trastornos de la piel y el cabello.
WO2017066712A3 (en) Modulators of telomere disease
Kobielak et al. Skin and skin appendage regeneration
WO2017066796A3 (en) Modulators of telomere disease
WO2012090194A3 (en) Compositions and methods for treating a skin disorder
MX2022008273A (es) Neurregulina para usarse en el tratamiento de lesion cardiaca.
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells
HK1201732A1 (en) Methods and compositions for treating and diagnosing acute myocardial infarction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18823586

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18823586

Country of ref document: EP

Kind code of ref document: A2